Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer
The company said all evaluable patients showed significant tumor uptake, supporting plans to move RAD301 into Phase 2 testing.
SEC filing
Latest
5 stories
Wednesday, September 9
Wednesday, August 26
Radiopharm advances three programs across RAD202, RAD101, and BetaBart
In August 2026 filings, Radiopharm Theranostics reported dose escalation clearances for two radiotherapeutics and a scheduled FDA meeting for a diagnostic imaging agent.
SEC filing (3)
Friday, July 31
Radiopharm reports RAD 101 Phase 2b hit, plans Phase 3, cash falls to $4.1M
The company also disclosed a partial response in a RAD 204 trial patient and a quarterly cash outflow that leaves under one quarter of runway before recent raises.
SEC filing
Monday, July 27
Radiopharm Theranostics prices $4.05 million ADS offering, adds ATM facility
The Australian radiopharmaceutical company raised capital through a direct placement and expanded its at-the-market program with Leerink Partners days apart in late July 2026.
SEC filing (2)
Wednesday, July 22
Radiopharm reports confirmed partial response in Phase 1 trial of RAD204
One patient in the highest-dose cohort hit a RECIST-confirmed partial response and stayed progression-free past seven months, the company said in a July 22, 2026 filing.
SEC filing